All Stories

  1. Continuous vs stent‐removal antibiotic prophylaxis after cystectomy: a retrospective analysis
  2. Validation of Cxbladder Triage Plus in Australian patients with haematuria: the AUSSIE study
  3. Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer
  4. Health-Related Quality of Life Among People Diagnosed with High-Risk Non-Muscle Invasive Bladder: Baseline Data from the ANZUP BCG + Mitomycin Clinical Trial
  5. Peripherally acting μ-opioid receptor antagonists for recovery of bowel function after radical cystectomy: a systematic review and meta-analysis
  6. The effect of delays in cancer surgery due to the COVID-19 pandemic on cancer resectability and postoperative mortality in different tumor entities
  7. The CAMUS Initiative: A Multiphase, Multicentre International Collaboration to Redefine Risk Stratification, Reporting, and Grading of Surgical Complications in Urology
  8. International Multicentre Analysis of Perioperative Complications Following Major Urologic Oncologic Surgery: Early Results from More than 130 000 Procedures from the CAMUS Collaborative
  9. Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. ...
  10. Reply to Tonghu Liu’s Letter to the Editor re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In pr...
  11. Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
  12. Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay
  13. 30-day postoperative mortality and the effects of hospital preparedness during the COVID-19 pandemic: a pooled analysis of prospective international cohort studies
  14. SUBDUE‐3: SUB‐urothelial DUrvalumab‐ 89 zirconium injEction; a phase 0 biodistribution study protocol
  15. Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)
  16. Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer
  17. The role of gemcitabine–docetaxel in the management of NMIBC: a scoping review of current status and future directions
  18. The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction
  19. Urothelial carcinoma in situ of the entire urinary tract with invasion into seminal vesicle: A case report
  20. G-DISCO: Phase 1 Study of Combined Chemotherapy for Bladder Cancer Treatment
  21. Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI
  22. Exercise and Psychosexual Education to Improve Sexual Function in Men With Prostate Cancer
  23. Massive tubular ectasia of the rete testes in a patient with Marfan syndrome
  24. A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol
  25. Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions
  26. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities
  27. Cystectomy for bilateral thigh fistulation after salvage radiotherapy for prostate cancer: A case report
  28. Development of a new radical cystectomy surveillance protocol and nurse‐led cystectomy follow‐up clinic in Australia
  29. Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort
  30. Immediate Versus Delayed Exercise on Health-related Quality of Life in Patients Initiating Androgen Deprivation Therapy: Results from a Year-long Randomised Trial
  31. An evaluation of durvalumab across the spectrum of urothelial carcinoma
  32. Postoperative anaemia increases unplanned readmission: an international prospective cohort study of patients undergoing major abdominal surgery
  33. A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts
  34. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
  35. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities
  36. Durvalumab Injection for Bladder Cancer: First-In-Human Trial
  37. Nurse‐led renal cell carcinoma clinic: a single center review
  38. FDG-PET vs CT in Staging Urothelial Cancer: Improving Metastasis Detection and Treatment Outcomes
  39. Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy
  40. Solitary fibrous tumour of the urinary bladder – A rare and potentially malignant neoplasm
  41. Relationship between lower urinary tract symptoms (LUTS) and prostate cancer: A persistent myth
  42. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
  43. The utility of clinical registries for guiding clinical practice in upper tract urothelial cancer: a narrative review
  44. Lymph node assessment technique matters in radical cystectomy for bladder cancer
  45. Efficacy and Feasibility of Presurgical Exercise in Bladder Cancer Patients Scheduled for Open Radical Cystectomy
  46. Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette–Guerin
  47. Analysis of the financial impact and efficiency of the One Stop Prostate Clinic: A same day prostate cancer diagnostic clinic in the Australian public health system
  48. Current trends in penile cancer survivorship amongst remote patients and Aboriginal people in Western Australia
  49. The Evolving Role of Locally Delivered Checkpoint Inhibitors in Non–muscle-invasive Bladder Cancer
  50. Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database
  51. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study
  52. 1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
  53. Nationwide Industry-Led Community Exercise Program for Men With Locally Advanced, Relapsed, or Metastatic Prostate Cancer on Androgen-Deprivation Therapy
  54. Nomogram predicting the probability of spontaneous stone passage in patients presenting with acute ureteric colic
  55. Intravesical hyaluronic acid with chondroitin sulphate to prevent urinary tract infection after spinal cord injury
  56. Anterior pelvic exenteration and synchronous bilateral nephroureterectomy for BK polyoma virus induced urothelial carcinoma of the bladder: A case report
  57. Weight loss for overweight and obese patients with prostate cancer: a study protocol of a randomised trial comparing clinic-based versus Telehealth delivered EXercise and nutrition intervention (the TelEX trial)
  58. Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer – A rare complication
  59. Technetium‐99 m‐sestamibi single‐photon emission computerised tomography (CT)/CT in the prediction of malignant versus benign small renal masses
  60. 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
  61. SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule.
  62. Unique case of IgG4-related disease of the renal pelvis involving the inferior vena cava masquerading as locally advanced urothelial cancer
  63. A novel technique to remove a urinary bladder foreign body endoscopically using an Endoloop
  64. Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis
  65. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
  66. TREXIT Is Now: Should We Abandon the Transrectal Route for Biopsy? A Three-continent Debate—No
  67. SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
  68. Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
  69. ‘Pain‐free TRUS B’: a phase 3 double‐blind placebo‐controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography‐guided prostate biopsy (ANZUP 1501)
  70. Nurse‐led telephone notification of a prostate cancer diagnosis: Prospective analysis of men's preferences for and experiences of a same‐day assessment and diagnostic clinic
  71. Abstract LB036: Clinical value of 18F-FDG-PET compared with CT scan in the detection of nodal and distant metastasis in urothelial carcinoma or bladder cancer
  72. Adenocarcinoma of the urethra: A rare subtype of urethral cancer
  73. A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial D...
  74. Timing of surgery following SARS-CoV-2 infection
  75. Transrectal ultrasound biopsy of the prostate: does it still have a role in prostate cancer diagnosis?
  76. Ten‐year outcomes of the first ‘one‐stop haematuria clinic’ in an Australian public hospital
  77. Multi-route antifungal administration in the management of urinary Candida glabrata bezoar
  78. Open partial nephrectomy for a collision renal cell carcinoma in a transplant kidney: A case report
  79. ‘One Stop Prostate Clinic’: prospective analysis of 1000 men attending a public same‐day prostate cancer assessment and/or diagnostic clinic
  80. Gender discrepancies in bladder cancer: potential explanations
  81. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]
  82. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
  83. Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer
  84. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
  85. Painless Visible Haematuria in Adults: An Algorithmic Approach Guiding Management
  86. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
  87. National Speakers
  88. Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the Multi‐centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute u...
  89. An inventive two-catheter technique to manage an extra-peritoneally ruptured and prolapsed bladder causing obstructive uropathy
  90. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition
  91. Co-existing renal myelolipoma and renal cell carcinoma: A case report
  92. Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial
  93. Intratesticular pseudoaneurysm secondary to orchitis: A case report
  94. Transrectal prostate biopsy sepsis rate following reduced quinolone antibiotic prophylaxis from six doses to single dose
  95. Metastatic primary testicular carcinoid tumor managed with radical orchiectomy, retroperitoneal lymph node dissection and inferior vena cava excision: Case report
  96. Delays in the diagnosis and initial treatment of bladder cancer in Western Australia
  97. BCG + Mitomycin trial for high‐risk non‐muscle‐invasive bladder cancer: progress report and lessons learned
  98. Bladder cancer – Old lessons yet to be learned
  99. Neobladder Obstruction: A Non-ischemic Cause for Hepatic Portal Venous Gas: Case Report
  100. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer
  101. Enhancing active surveillance of prostate cancer: the potential of exercise medicine
  102. Pure small cell carcinoma of the prostate preceded by acute zonal occult outer retinopathy: A case report
  103. A ‘One Stop’ Prostate Clinic for rural and remote men: a report on the first 200 patients
  104. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
  105. Retrograde ureteric stent insertion in the management of infected obstructed kidneys
  106. The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group – a new co‐operative cancer trials group in genitourinary oncology
  107. Radical cystectomy in Australia
  108. A randomised controlled trial comparing use of lignocaine periprostatic nerve block alone and combined with diclofenac suppository for patients undergoing transrectal ultrasound ( TRUS )‐guided prostat...
  109. The conservative management of renal trauma: a literature review and practical clinical guideline from A ustralia and N ew Z<...
  110. Using mobile technology to overcome language barriers in medicine
  111. Current trends in bladder cancer in Australia
  112. The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART
  113. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer
  114. First Report of the Stapled Mesh Stoma Reinforcement Technique in a Urologic Context
  115. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis
  116. Intravesical therapies for bladder cancer – indications and limitations
  117. ‘One stop’ haematuria clinic in Fremantle Hospital, Western Australia: a report of the first 500 patients
  118. Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: ...
  119. EORTC radiation proctitis-specific quality of life module – Pretesting in four European countries
  120. Ultrasensitive Prostate Specific Antigen Assay Following Laparoscopic Radical Prostatectomy – An Outcome Measure for Defining the Learning Curve
  121. Hyperbaric Oxygen Treatment of Chronic Refractory Radiation Proctitis: A Randomized and Controlled Double-Blind Crossover Trial With Long-Term Follow-Up: In Regard to Clarke et al. (Int J Radiat Oncol Biol Phys 2008 Mar 12)
  122. Nanotechnology and Its Relevance to the Urologist
  123. Delayed presentation of arteriovenous fistula 20 years after blunt renal trauma
  124. Survey of Endourology
  125. NURSE‐LED FLEXIBLE CYSTOSCOPY: EXPERIENCE FROM ONE UK CENTRE
  126. A Prospective, Randomized Trial Comparing Conventional Transurethral Prostate Resection With PlasmaKinetic® Vaporization of the Prostate: Physiological Changes, Early Complications and Long-Term Followup
  127. Randomized, placebo‐controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks
  128. 1449: Finasteride Rapidly Reduces Prostatic Vascularity: A Randomized Placebo Controlled Study
  129. New phosphodiesterase inhibitors in the treatment of erectile dysfunction
  130. Allogeneic stem-cell transplantation for renalcellcancer
  131. CURRENT TRENDS IN BLADDER CANCER IN ENGLAND AND WALES
  132. Pharmacological management of metastatic boney pain
  133. Physiologic Changes of the Anorectum After Pelvic Radiotherapy for the Treatment of Prostate and Bladder Cancer
  134. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer
  135. Current Trends in Colorectal Cancer: Site, Incidence, Mortality and Survival in England and Wales
  136. First Report of an Isolated Jejunal Seminoma: Presentation with Melaena and Iron Deficiency Anaemia
  137. HEMANGIOPERICYTOMA OF THE SEMINAL VESICLE PRESENTING WITH HYPOGLYCEMIA
  138. HEMANGIOPERICYTOMA OF THE SEMINAL VESICLE PRESENTING WITH HYPOGLYCEMIA
  139. Primary anterior urethral transitional cell carcinoma: a rare tumour
  140. Anorectal injury following pelvic radiotherapy
  141. Anorectal Irradiation in Pelvic Radiotherapy: An Assessment Using in-vivo Dosimetry
  142. Massive Mediastinal Seminoma Post-orchidectomy Late relapse with Skip-metastases or New Primary?